Its latest collaboration along with Gavi and the Bill and Melinda Gates Foundation brings the total number of vaccine doses to be covered to an aggregate of up to 200 million doses.
Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city.
Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study
Will adhere to DCGI instructions: Serum Institute on show cause over not pausing trial of COVID-19 vaccine
The Serum Institute said in its statement that they were not instructed to pause trials.
The drug regulator's move comes after AstraZeneca, which is developing the vaccine candidate against COVID-19 with researchers of Oxford University
Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford.
Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.
The vaccine candidate is under advanced stages of clinical trials and likely to be available for public use in the first half of 2021.
The company has set an affordable ceiling price of USD 3 (around Rs 225) per dose, it added.
The SEC on COVID-19 which held its meeting on Tuesday deliberated on the application by SII and asked the Pune-based firm to revise its protocol for the phase 2 and 3 clinical trials.
About 6,000 health workers and high-risk individuals including those in close contact of COVID-19 patients have been enrolled in the clinical trial.
Adar Poonawalla, while replying to a tweet by film producer Ronnie Screwvala, however, did not specify the quantity of the doses that will be kept for the community.
Serum Institute of India seeks DCGI nod for phase 2, 3 clinical trials of Oxford vaccine for COVID-19
The sources told PTI that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of the vaccine candidate 'Covishield'.